SecBot SecBot
8-K ·Filed Jun 29, 2026

TCRT

Alaunos Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed4mo ago SEC0001193125-26-286914
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

The preclinical data is supportive but early-stage and non-GLP. The critical near-term catalyst is the company's ability to secure financing given the minimal cash runway. Monitor for equity or debt offerings, partnership announcements, or IND-enabling study updates.

DirectionNeutral
Confidencehigh
Horizonweeks

ALN1003

▼ Bearish Named in this 8-K
Impact
Phase
Preclinical
Time to market
Unknown — still preclinical; IND-enabling studies not yet started; likely 5+ years away from any potential approval assuming financing and successful clinical development
Next catalyst
None dated

What to watchALN1003 is too early-stage to drive a catalyst-based trade. The only near-term binary is financing: watch for a dilutive equity offering or reverse split. Without a capital infusion, the company cannot fund IND-enabling studies. This is a speculative story stock, not a drug catalyst play.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$2.37
T+0 close · Jun 29, 2026 · via day close
Latest settled
−46.41%
T+60 · $1.27
Vs SPY
−50.80%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 29 $2.37entry
  2. T+1 · 5mo ago −4.64%α −5.42% · $2.26
  3. T+5 · 4mo ago −9.28%α −10.67% · $2.15
  4. T+20 · 4mo ago −18.14%α −17.86% · $1.94
  5. T+60 · 8w ago −46.41%α −50.80% · $1.27
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alaunos Therapeutics announced new preclinical statistical analysis for ALN1003, showing lower liver weight after adjusting for body fat percentage in a 48-day DIO mouse study. The data is directionally consistent with prior liver marker and biomarker findings, but remains non-GLP preclinical with no human trials. The company had only ~$0.354M cash as of March 31, 2026, and will need additional financing to continue development.

Key Facts

  • ALN1003-treated animals showed lower liver weight after adjustment for body fat percentage (ANCOVA p=0.000005; HC3 robust p=0.000015) in a 48-day DIO mouse study.
  • Findings are directionally consistent with previously disclosed lower liver injury enzymes, lower NAFLD Activity Scores (NAS), lower HOMA-IR, and favorable adipose endocrine biomarkers.
  • ALN1003 has not been evaluated in human clinical trials; safety and efficacy in humans not established.
  • As of March 31, 2026, the company had cash and cash equivalents of approximately $0.354 million and intends to pursue additional financing.
  • Data is from non-GLP preclinical studies with limitations including small sample sizes, post hoc analysis, and indirect liver weight measures.

Financial Impact

No revenue or material financial impact. Cash position of ~$0.354M as of March 31, 2026, necessitates near-term financing for continued operations.

cash

Risk Factors

  • Cash runway is extremely limited (~$0.354M) and the company will likely need to raise capital imminently, causing dilution.
  • Preclinical mouse data may not translate to human clinical outcomes; ALN1003 has not been tested in humans.
  • Non-GLP study limitations and post hoc analysis reduce the reliability of the findings.
  • Competition in the obesity/metabolic disease space is intense, with many well-funded players.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-286914
Document: tcrt-ex99_1.htm0001193125-26-286914
Document: 0001193125-26-286914-index-headers.html0001193125-26-286914
Document: 0001193125-26-286914-index.html0001193125-26-286914
Document: 0001193125-26-286914.txt0001193125-26-286914

Track record

14 reports on TCRT

Performance horizon

2 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +26.36% at T+60 after the Apr 15, 2026 report. 4 of 9 went positive at some point.

Filters
  1. Nov 12, 20264d ago S-3 Bearish 6/10 Entry $1.63 Now $1.60 +1.84% settles Dec 14
  2. Oct 23, 202624d ago 8-K Bullish 5/10 Entry $2.13 Now $1.60 −24.88% settles Nov 23
  3. Oct 21, 202626d ago 8-K Bullish 7/10 Entry $3.04 Now $1.60 −47.37% settles Nov 19
  4. Oct 15, 20264w ago SC 13D/A Neutral 6/10 Entry $2.63 to $1.63 Now $1.60 −39.16% ▼ −38.02% −36.86% vs SPY
  5. Oct 15, 20264w ago SC 13D Neutral 5/10 Entry $2.63 to $1.63 Now $1.60 −39.16% ▼ −38.02% −36.86% vs SPY
  6. Oct 13, 20264w ago Press Release Bullish 8/10 Entry $3.03 to $1.67 Now $1.60 −47.19% ▼ −44.88% −41.21% vs SPY
  7. Oct 13, 20264w ago 8-K Bullish 8/10 Entry $3.03 to $1.71 Now $1.60 −47.19% ▼ −43.56% −39.95% vs SPY
  8. Oct 9, 20265w ago 8-K Bearish 7/10 Entry $1.05 to $1.67 Now $1.60 −52.38% ▼ −59.05% −62.31% vs SPY
  9. Sep 18, 20268w ago Press Release Bearish 5/10 Entry $1.20 to $2.63 Now $1.60 −33.33% ▼ −119.17% −118.96% vs SPY
  10. Sep 16, 20268w ago 8-K Neutral 2/10 Entry $1.60 to $2.18 Now $1.60 +0.00% ▲ +36.25% +34.79% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 6h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 3, 2026